A Study of Disitamab Vedotin Combined With Tislelizumab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in HER2-Low Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06944496 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

616

Enrollment

INDUSTRY

Sponsor class

Conditions

Gastric Carcinoma

Interventions

BIOLOGICAL: Disitamab Vedotin+Tislelizumab+Oxaliplatin+Capecitabine
BIOLOGICAL: Tislelizumab+Oxaliplatin+Capecitabine

Sponsor

RemeGen Co., Ltd.